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Short running title: Influenza vaccine to reduce antibiotic use 26 
27 
  
Synopsis (250/250): 28 
Background: Influenza infections result in both inappropriate and appropriate antibiotic 29 
prescribing. There is a huge burden of both influenza and infections with antimicrobial 30 
resistant (AMR) pathogens in Africa. Influenza vaccines have the potential to reduce 31 
both appropriate antibiotic use, through the reduction in secondary bacterial infections, 32 
as well as to reduce levels of influenza misdiagnosed and treated as a bacterial infection 33 
(inappropriate).  34 
Objectives: To estimate potential reductions in antibiotic use achievable by introducing 35 
an influenza vaccine to various African settings. 36 
Methods: Influenza incidence was combined with population size, vaccine and health 37 
system characteristics.  38 
Results: We estimated that the direct impact of vaccination could avert more than 390 39 
prescriptions per 100,000 population per year if a 50% efficacious influenza vaccine at 40 
30% coverage were introduced to adults >65 years old (yo) in South Africa or children 41 
2 - 5 yo in Senegal. Across Africa, purely through reducing the number of severe acute 42 
respiratory infections, the same vaccine characteristics could avert at least 24,000 43 
antibiotic prescriptions per year if given to children < 5 years.  44 
Conclusions: The introduction of an influenza vaccine into multiple African settings 45 
could have a dramatic indirect impact on antibiotic usage. Our values are limited 46 
underestimates, capturing only the direct impact of vaccination in a few settings and 47 
risk groups. This is due to the huge lack of epidemiological information on antibiotic 48 
use and influenza in Africa. However, it is likely that influenza vaccination in Africa 49 
could substantially impact antibiotic usage in addition to influenza-related mortality 50 
and morbidity.  51 
52 
  
Background 53 
Antimicrobial resistance (AMR) is a global concern. The rise in resistance, in part, is 54 
attributed to inappropriate use of antibiotics such as for misdiagnosed viral infections, 55 
including influenza. Currently, the capacity to tackle misdiagnosis is lacking in many 56 
low and middle-income countries (LMICs). A recent review of AMR in Africa 57 
highlighted high levels of resistance to antibiotics commonly used for respiratory tract 58 
infections.1 Moreover, West and Southern Africa had among the greatest increases 59 
globally in per person antibiotic consumption between 2000 and 2010.2 60 
 61 
Influenza infections result in increased antibiotic prescribing to treat secondary 62 
bacterial infections (appropriate) and primary influenza cases misdiagnosed as bacterial 63 
infections (inappropriate). An indirect benefit of influenza vaccination could be to 64 
reduce antimicrobial prescribing, and ultimately, AMR. However, both the burden of 65 
influenza and use of influenza vaccines in Africa have been neglected. A study of 15 66 
African countries demonstrated that influenza accounted for 21.7% of influenza-like 67 
illness (ILI) and 10.1% of severe acute respiratory infection (SARI) cases.3 A recent 68 
systematic analysis found that the per capita influenza-associated hospitalization rate 69 
in children < 5 years was > 3-fold higher in Africa as compared to Europe.4 70 
 71 
In 2012, the WHO Strategic Advisory Group of Experts recommended influenza 72 
vaccination in key high-risk groups: Pregnant women (with potential protection for the 73 
neonate), children aged 6 – 59 months, the elderly, healthcare workers and those with 74 
specific chronic medical conditions. However, a recent analysis found that only three 75 
African countries (of 47 WHO member states) had implemented seasonal influenza 76 
vaccine policies.5  77 
  
 78 
The Global Alliance for Vaccines and Immunization (GAVI) foundation, a major 79 
vaccine funder, has proposed immunisation as a key strategy in combating AMR, but  80 
one which requires more research to guide intervention prioritisation.6 The potential for 81 
influenza vaccines to reduce antibiotic prescribing has been determined in only one 82 
study from Ontario, Canada, where an association between a 64% reduction in 83 
antibiotic prescriptions and roll out of a universal influenza immunisation programme 84 
was demonstrated.7 The impact of influenza vaccine rollout on antibiotic usage in 85 
Africa is currently unknown. 86 
 87 
In the absence of direct trial data, we combined data from a range of sources to predict 88 
the potential number of antibiotic prescriptions that could be directly avoided by 89 
influenza vaccine rollout in various African populations, taking into account variability 90 
in healthcare (and therefore antibiotic) availability and vaccine coverage. These 91 
estimates should stimulate further discussion and research on the wider benefits of 92 
influenza vaccine rollout in African countries with currently low influenza vaccine 93 
coverage, high influenza burden, high level of antibiotic use and rising levels of AMR.  94 
 95 
96 
  
Materials and Methods 97 
 98 
Data on influenza incidence 99 
There is limited information on many aspects required to comprehensively estimate the 100 
impact of influenza vaccination on antibiotic prescribing across Africa. Hence, we 101 
included only the number of (1) appropriate antibiotic prescriptions following SARI 102 
and (2) inappropriate antibiotic prescriptions following influenza-related ILI in 103 
example settings. We identified studies that provided robust estimates of influenza-104 
related ILI or SARI in different high-risk groups from a number of African countries, 105 
either via attack rates in placebo recipients enrolled in randomized clinical trials (RCT) 106 
or epidemiological studies and systematic reviews (Table S1). We did not include the 107 
indirect impact of vaccination on secondary influenza cases due to a lack of data on 108 
influenza transmission dynamics from African settings.  109 
 110 
Calculating antibiotic use 111 
We split antibiotic use into two components: (1) likelihood that someone with an ILI 112 
or SARI would be prescribed antibiotics and (2) likely provision of healthcare and 113 
antibiotics in a setting. These were multiplied to give a level of antibiotic prescribing.  114 
 115 
For (1) we assumed that SARI cases would usually fulfil criteria in clinical guidelines 116 
for prescribing antibiotics (e.g. WHO integrated management of childhood illness) and 117 
therefore, that if available, 100% would be prescribed antibiotics. The available 118 
literature suggests that the proportion with ILI that receive an (inappropriate) antibiotic 119 
is higher in LMICs than in high income settings (Text S1), hence we assumed in our 120 
  
calculations that 70% of influenza-associated ILI would inappropriately be prescribed 121 
antibiotics.  122 
 123 
We assumed that coverage of health care provision and antibiotic availability was 50%. 124 
Thus, even if 100% of SARI patients would ordinarily be given antibiotics, only 50% 125 
of them would receive antibiotics. The aim of this parameter was to reflect health 126 
system failings in LMIC settings where antibiotics may not always be available despite 127 
prescription or where SARI-related deaths occur outside a healthcare setting.  128 
 129 
Population size estimates 130 
Data from the World Bank for 2015 was used to generate population size estimates 131 
(Text S1). 132 
 133 
Vaccine characteristics & coverage 134 
We assumed vaccine effectiveness was 50% based on various international estimates.8 135 
We considered a low vaccine coverage of 30%. In the Tables S2, we provide estimates 136 
for higher health care provision and antibiotic availability (80%) and 90% vaccine 137 
coverage. The high vaccine coverage figure was based on studies in The Gambia, where 138 
uptake of infant immunisations reaches >90% in many cases.9 139 
140 
  
Results 141 
 142 
The overall estimates for the impact of an influenza vaccine programme targeting key 143 
high-risk groups is shown in Table 1. With low vaccine coverage (30%) and antibiotic 144 
availability at 50%, the number of prescriptions that could be averted by targeting each 145 
risk group is between 15 – 945 per 100,000 population per year. Of the populations 146 
considered, the lowest estimates come from targeting those >65 yo in Ghana, the 147 
highest from targeting adults >65 yo in South Africa or children 2 - 5 yo in Senegal.  In 148 
a corresponding measure, 5 – 315 antibiotic prescriptions could be averted per 10,000 149 
vaccinations.  150 
 151 
Two studies provided estimates for SARI incidence only in children <5 yo across 152 
Africa.4, 10 Using these, we estimated that just the impact on avoiding appropriate 153 
antibiotic use for these most serious cases with the introduction of influenza vaccine at 154 
30% coverage could prevent at least 24,000 antibiotic prescriptions per year (13 [95% 155 
CI 7, 26] per 100,000 population per year).  156 
 157 
158 
  
Discussion 159 
 160 
We aimed to estimate the impact of influenza vaccines on antibiotic use in Africa, using 161 
the current limited data available. Our conservative direct impact estimates suggest that 162 
a large number of antibiotic prescriptions could be averted across Africa each year, 163 
even with low coverage of an influenza vaccine.  164 
 165 
Our estimates were limited by a lack of data. More data is needed on both influenza 166 
and secondary bacterial infection incidence, as well as antibiotic exposure levels (by 167 
age) to allow calculation of influenza “attributable prescribing”.11 Complexity in 168 
determining influenza vaccine impact would also involve modelling vaccine campaign 169 
timing (with varying influenza seasonality across Africa) and variation in coverage in 170 
different risk populations. Vaccine efficacy may also vary in different risk populations 171 
(e.g. due to immunosenescence), as well as due to seasonality and influenza antigenic 172 
drift. Moreover, high HIV prevalence in certain settings, alongside substantial variation 173 
in access to healthcare (and hence antibiotic prescribing) could make estimates highly 174 
setting-specific. We included an antibiotic “availability” parameter, but to our 175 
knowledge, there are no studies that explore the relative ease of antibiotic accessibility 176 
across Africa (e.g. impact of unsanctioned providers, health system quality or 177 
rural/economic setting) or health seeking behaviour differences.  178 
 179 
Our evaluation is an underestimate, not only as we likely use conservative vaccine 180 
coverage (30%) and antibiotic availability (50%) values, but as we do not include the 181 
indirect impact of vaccination on secondary cases of influenza. Reduction in influenza 182 
transmission in the community by vaccinating high-risk groups may significantly 183 
  
enhance the impact observed. A recent modelling study of the German population 184 
suggested that 4-7x as many influenza cases are prevented among non-vaccinated 185 
individuals as among vaccinees.12 Due to a lack of data, our estimates also only 186 
considered the number of ILI or SARI cases averted by the vaccine. Only a minority of 187 
risk groups (e.g. ≥ 65 yos in Ghana) had data on both ILI and SARI incidence (Table 188 
1). Hence our estimates are an underestimate of even the combined direct impact of 189 
vaccination.  190 
 191 
Several agencies (e.g. GAVI) are now calling for the use of vaccines to help in the 192 
prevention of AMR.11 However, as in our work here, whilst the impact on antibiotic 193 
prescribing can be estimated, the jump to impact on AMR is challenging to make.13 194 
Without this link, the likely dramatic impact of influenza vaccine on antibiotic usage, 195 
and subsequent AMR levels in Africa cannot be estimated.  196 
 197 
The estimates we make here should be expanded as more data on influenza, and 198 
antibiotic use become available. Importantly, future trials in LMICs should consider 199 
linking outcomes across public health measures: influenza vaccine trials could be 200 
designed to capture impact on antibiotic usage in addition to preventing influenza 201 
infections. 202 
 203 
Influenza vaccines could have a dramatic impact on morbidity and mortality in Africa. 204 
The reasons for the lack of influenza vaccine programmes across the continent are 205 
multifactorial, including health economic ones. Yet policy decisions are often made by 206 
considering prevention of influenza infections as the sole beneficial outcome. Although 207 
public health interventions such as vaccination are costly, as highlighted by our 208 
  
estimates, the wider benefits may be substantial, and with increasing evidence should 209 
be included as key considerations. 210 
211 
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 260 
 Number of prescriptions averted per year (mean [range]) 
Pop. Setting ILI SARI Total 
Per 100,000 
population  
Per 10,000 
vaccinations  
≥ 65 yo 
S.A. x  11,153 399 133 
Ghana x x 140 [125,157] 15 [13, 17] 5 [4.5,5.6] 
< 5 yo 
 
 
 
Kenya x  9,425 [6,492,13,655] 135 [93, 195] 44.9 [30.9,65.1] 
Ghana x x 
8,456 [8,233,8,691] 210 [205, 216] 70.1 [68.2,72] 
(2-5yo) Senegal x  13,772 945 315.0 
 < 6 mo 
S. A. x  1,094 189 63.0 
Mali x  505 147 49.0 
Kenya x x 894 [254,3,434] 128 [36, 491] 42.6 [12.1,163.7] 
Pregnant 
S. A.  x  1,661 189 63.0 
Mali x  565 100 33.3 
< 5 yo 
Africa*  x  24 [12,49]* 13 [7, 26]  4.4 [2.2,8.7]  
Africa*  x  25 [14,47]* 14 [7, 25]  4.5 [2.4,8.3]  
Table 1: The estimated number of antibiotic prescriptions that could be averted per year by the introduction of an influenza vaccine into specific 261 
high-risk groups in Africa, where we could find sufficient data. A cross (“x”) indicates where estimates came from: ILI, SARI or both. The range 262 
given is a 95% confidence interval (CI) except for Kenyan data where it is minimum-maximum. See Table S1 for sources of incidence data for 263 
each example. Vaccine effectiveness was assumed to be 50%, vaccine coverage 30% and antibiotic availability at 50%. Estimates for other 264 
  
coverage and antibiotic availability are found in Tables S2. *Note that the values for the estimates for the African setting total are in thousands 265 
of prescriptions. S.A. = South Africa. “mo”: months old. “yo”: years old.  266 
